The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people

Clinical Medicine and Research

Volumn 8, Issue 2, 2010, Pages 89-95

  Unek, Ilkay Tugba ^a   Bayraktar, Firat ^a   Solmaz, Dilek ^a   Ellidokuz, Hulya ^a   Sisman, Ali Riza ^a   Yuksel, Faize ^a   Yesil, Sena ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Body mass index; C reactive protein; CD40 ligand; Inflammation; Obesity

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; INFLAMMATION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; OBESITY; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; WAIST CIRCUMFERENCE; BLOOD; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; C-REACTIVE PROTEIN; CD40 LIGAND; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT;

EID: 77957235564     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.2010.889     Document Type: Article

References (53)

1. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004;53:495-499.
2. Kopelman PG. Obesity as a medical problem. Nature 2000;404:635-643.
3. Piché ME, Lemieux S, Weisnagel SJ, Corneau L, Nadeau A, Bergeron J. Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am J Cardiol 2005;96:92-97.
4. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. [Obesity, inflammation and insulin resistance: which role for adipokines.] [Article in French] Therapie 2007;62:285-292.
5. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008;34:2-11.
6. Mohamed-Ali V, Pinkey JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998;22:1145-1158.
7. Flores-Alfaro E, Parra-Rojas I, Salgado-Bernabé AB, Chávez-Maldonado JP, Salazar-Martinez E. Cardiovascular risk evaluated by C-reactive protein levels in diabetic and obese Mexican subjects. Circ J 2008;72:1170-1174.
8. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-978.
9. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-2135.
10. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, Hofman A, Witteman JC. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middleaged women. Arterioscler Thromb Vasc Biol 1999;19:1986-1991.
11. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799-1804.
12. Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242.
13. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002;106:2908-2912.
14. Haffner SM. Insulin resistance, inflammation, and prediabetic state. Am J Cardiol 2003;92:18J-26J.
15. Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001;58:4-43.
16. Schönbeck U, Mach F, Libby P. CD154 (CD40 ligand). Int J Biochem Cell Biol 2000;32:687-693.
17. André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Plateletderived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002;106:896-899.
18. Schönbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001;89:1092-1103.
19. Phipps RP. Atherosclerosis: The emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA 2000;97:6930-6932.
20. Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001;104:2266-2268.
21. Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M, Goppelt-Struebe M, Schmieder R, Daniel WG. Upregulation of CD40 and CD40 Ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001;104:2395-2400.
22. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, Falco A. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002;106:399-402.
23. Semb AG, van Wissen S, Ueland T, Smilde T, Waehre T, Tripp MD, Froland SS, Kastelein JJ, Gullestad L, Pedersen TR, Aukrust P, Stalenhoef AF. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 2003;41:275-279.
24. Jinchuan Y, Zonggui W, Jinming C, Li L, Xiantao K. Upregulation of CD40-CD40 ligand system in patients with diabetes mellitus. Clinica Chim Acta 2004;339:85-90.
25. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, Fernández-Cruz A, Veves A, Jarolim P, Varo JJ, Goldfine A, Horton E, Schönbeck U. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003;107:2664-2669.
26. Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Frøland SS, Gullestad L. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100:614-620.
27. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schönbeck U. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003;108:1049-1052.
28. Garlichs CD, Eskafi S, Raaz D, Schmidt A, Ludwig J, Herrmann M, Klinghammer L, Daniel WG, Schmeisser A. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001;86:649-655.
29. Peng DQ, Zhao SP, Li YF, Li J, Zhou HN. Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clinica Chim Acta 2002;319:19-26.
30. Desideri G, Feri C. Effects of obesity and weight loss on soluble CD40L levels. JAMA 2003;289:1781-1782.
31. Schernthaner GH, Kopp HP, Krzyzanowska K, Kriwanek S, Koppensteiner R, Schernthaner G. Soluble CD40L in patients with morbid obesity: significant reduction after bariatric surgery. Eur J Clin Invest 2006;36:395-401.
32. Guldiken S, Demir M, Arikan E, Turgut B, Azcan S, Gerenli M, Tugrul A. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: Soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res 2007;119:79-84.
33. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-3167.
34. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996;312:1061-1065.
35. Pieroni L, Bastard JP, Piton A, Khalil L, Hainque B, Jardel C. Interpretation of circulating C-reactive protein levels in adults: body mass index and gender are a must. Diabetes Metab 2003;29:133-138.
36. Festa A, D'Agastino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001;25:1407-1415.
37. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-466.
38. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 2002;23:831-834.
39. Yeh ET, Anderson HV, Pasceri V, Willerson JT. C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001;104:974-975.
40. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
41. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
42. Ridker PM, Buring JE, Cook NR, Rifai N. C-Reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-397.
43. Mach F, Schönbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394:200-203.
44. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura L. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-1761.
45. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002;288:2008-2014.
46. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P, Violi F. gp91phox-dependent expression of platelet CD40 ligand. Circulation 2004;110:1326-1329.
47. Foschini D, Santos RV, Prado WL, de Piano A, Lofrano MC, Martins AC, Carnier J, Caranti DA, Sanches Pde L, Tock L, Mello MT, Tufik S, Dâmaso AR. Platelet and leptin in obese adolescents. J Pediatr (Rio J) 2008;84:516-521.
48. Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract 2005;59:981-982.
49. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278-301.
50. Angelico F, Alessandri C, Ferro D, Pignatelli P, Del Ben M, Fiorello S, Cangemi R, Loffredo L, Violi F. Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation. Diabetologia 2006;49:1169-1174.
51. Baron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 2000;102:2329-2334.
52. Yip HK, Wu CJ, Hang CL, Chang HW, Yang CH, Hsieh YK, Fang CY, Fu M, Yeh KH, Chen MC. Levels and values of inflammatory markers in patients with angina pectoris. Int Heart J 2005;46:571-581.
53. Poirier P, Eckel RH. Obesity and cardiovascular disease. Curr Atheroscler Rep 2002;4:448-453.